Company / Free Cash Flow
Ultragenyx Pharmaceutical Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$472.0M
FY2025
5-year range
-$519.0M / -$370.2M
FY2021-FY2025
Trend
-12.1%
vs FY2024
Sector context
#185 of 194
Health Care
What the data says
Among 194 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 5% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$519M in FY2023 to -$47M in FY2016.
Based on SEC 10-K filings.
-$472M in FY2025.
Improved from -$519M to -$472M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 194This company -$472.0M Sector average $470.6M
▼
-200.3% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 12.1% year-over-year.
- Ranks #185 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$472.0M | -12.1% |
| FY2024 | -$421.0M | +18.9% |
| FY2023 | -$519.0M | -4.5% |
| FY2022 | -$496.6M | -34.1% |
| FY2021 | -$370.2M | -25.6% |
| FY2020 | -$294.6M | -14.8% |
| FY2019 | -$256.6M | +12.9% |
| FY2018 | -$294.6M | -165.6% |
| FY2017 | -$110.9M | -137.1% |
| FY2016 | -$46.8M | +57.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026